olaparib for Breast

"Clinicaltrials.gov displays that this research project, which began on February 21st 2010 and was last updated October 4th 2022, is not seeking participants currently; however there are 195 other medical trials actively recruiting patients at the present time."

"At this juncture, recruitment for the clinical trial has ceased. The study was first made available on February 21st 2010 and last updated October 4th 2022. If you are looking to participate in further medical studies, 7 trials related to prostate cancer and 188 related to olaparib currently have open enrolment programs."

"Presently, there are 188 separate clinical investigations of olaparib active in 59 countries and 1468 cities. The first assessment occurred back in 2005 and was sponsored by AstraZeneca; it involved 98 individuals and achieved Phase 1 drug approval status. In the 15 years since then, 63 additional trials have been conducted."

"Considering the Phase 2 status of olaparib, which has data to support safety but not yet efficacy, our team at Power assigned it a rating of 2."

"This clinical trial is available to adults that are over 18 years old and no more than 130 years of age."

"At present, there are 188 clinical trials actively studying olaparib with 27 of them in the final stage. While Houston is a major hub for these studies, they span 9250 sites throughout the world."

"This particular medical study is searching for 298 subjects aged 18 to 130 with prostate cancer, who further have confirmed deleterious or suspected deleterious BRCA mutations. Additionally, these participants must also have a malignant solid tumour without an existing treatment protocol and at least one measureable lesion that can be accurately assessed via CT/MRI scans."

"Olaparib is popularly prescribed to treat advanced forms of cancer, such as malignant neoplasm of the ovary and primary peritoneal cancer. It can also be beneficial for managing hallucinations or somatic symptoms."